

28 October 2021

DyeVert™ is highlighted by leading experts for reduction of Acute Kidney Injury

Minnesota, United States and Melbourne, Australia – 28 October 2021 – Osprey Medical, Inc. (ASX:OSP) (**Osprey or the Company**) is pleased to announce their DyeVert™ technology has been featured in multiple outlets detailing its use in reducing Contrast Induced Acute Kidney Injury (AKI). Strategic partner, GE Healthcare sponsored a special report that was published by Global Business Media outlining steps to reduce AKI including the DyeVert™ System. Additionally, the DyeVert technology was highlighted in two presentations including the **Complex Higher-Risk and Indicated Patients (CHIP)** congress in Italy, Milan from 15th- 16th October 2021 and the GE sponsored webinar titled *'Acute Kidney Injury (AKI) in complex high risk interventional catheter lab procedures'* on 20th October 2021.

'The Hospital Report', published by Global Business Media titled *'Three Perspectives on the Reduction of Contrast Induced Acute Kidney Injury in Invasive Cardiology'*, contains three articles by leading experts across Europe on Contrast Induced Acute Kidney Injury (AKI). The DyeVert system was featured in each of the articles as part of an AKI mitigation strategy.

The paper is available online and can be accessed at: http://www.hospitalreports.org/special_reports.html.

At the CHIP congress in Malian, Dr. Federico Ronco gave a lecture titled *'How to reduce the risk of AKI for complex cardiac interventions'*. Dr Ronco presented the challenges of CHIP patients and their high risk of AKI, describing solutions to reduce the risk of AKI including Osprey's DyeVert system.

Lastly, the DyeVert technology was featured as part of the *'Acute Kidney Injury (AKI) in complex high risk interventional catheter lab procedures'* webinar. The session was hosted by Professor Jonathan Sackier with guest speakers Dr. Peter McCullough and Prof. Emmanouil Brilakis. They discussed the importance of reducing AKI in high-risk patients including Osprey's DyeVert system for contrast reduction.

Osprey Medical CEO, Mr Mike McCormick commented:

"It is pleasing to see Osprey's DyeVert technology featured in many important events with key opinion leaders and industry experts. Increased exposure at these meetings and webinars allows global health professionals to hear about the DyeVert system and its efficacy in reducing AKI. Further, we are pleased to see continued promotion from strategic partner GE Healthcare which speaks to our strengthening relationship with the conglomerate. Our strategic partnership with GE continues to be beneficial for both companies as highlighted by an 80% increase in European sales from the previous quarter."

This release has been authorised for lodgement to ASX by Mike McCormick, CEO of Osprey Medical.

– ENDS –

Contact details:

Osprey Medical

Doug Schoenberg

VP of Marketing

T: +1 (952) 955 8230

dschoenberg@ospreymed.com

Investors

Prash Jitendran

Vesparum Capital

T: +61 3 8582 4800

ospreymed@vesparum.com

Media Relations

Ciara Byrne

Mana Communications

T: +61 41 3519 430

cb@manacommunications.com

About Osprey Medical (ASX: OSP)

Osprey Medical's vision is to make heart imaging procedures safer for patients with poor kidney function. The amount of dye (contrast) used during angiographic imaging procedures increases the patient's risk for dye-related kidney damage known as Contrast-Induced Acute Kidney Injury (CI-AKI). The Company's core technologies originated from research conducted by Dr David Kaye at Melbourne's Baker Institute. Its proprietary dye reduction and monitoring technologies are designed to help physicians minimize dye usage and monitor the dose of dye real time throughout the procedure. The Company's DyeVert™ System reduces contrast while maintaining image quality in a self-adjusting easy-to-use design that monitors dye usage. Osprey Medical's Board and Management are comprised of experienced and successful personnel with established track records covering medical device development, regulatory approvals, sales and marketing, and mergers-acquisitions. Osprey Medical's advisory board comprises world-recognised experts in heart and kidney diseases.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions, and expectations and on information currently available to management. Forward-looking statements involve known and unknown risks, uncertainties, contingencies and other factors, many of which are beyond the Company's control (including but not limited to the COVID-19 pandemic), subject to change without notice and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to commercialize our products including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Given the current uncertainties regarding the impact of the COVID-19 on the trading conditions impacting the Company, the financial markets and the health services world-wide, investors are cautioned not to place undue reliance on the current trading outlook.

Osprey does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Osprey may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

Foreign Ownership Restriction

Osprey's CHES Depositary Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers or sales which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. The holders of Osprey's CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.